An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer

British Journal of Cancer

Volumn 103, Issue 12, 2010, Pages 1835-1839

  Querzoli, P ^a   Coradini, D ^b   Pedriali, M ^a   Boracchi, P ^b   Ambrogi, F ^b   Raimondi, E ^b   La Sorda, R ^c   Lattanzio, R ^c   Rinaldi, R ^a   Lunardi, M ^a   Frasson, C ^a   Modesti, F ^a   Ferretti, S ^a   Piantelli, M ^c   Iacobelli, S ^c   Biganzoli, E ^b,d   Nenci, I ^a   Alberti, S ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

breast cancer; E cadherin; prognosis

Indexed keywords

UVOMORULIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CASE STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCORING SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CADHERINS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS;

EID: 78650035848     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605991     Document Type: Article

References (39)

1. Asgeirsson KS, Tryggvad JG, Olafsd J, Olafsdóttir K, Sigurgeirsdóttir JR, Ingvarsson S, Ogmundsdóttir HM (2000) Altered expression of E-cadherin in breast cancer: Patterns, mechanisms and clinical significance. Eur J Cancer 36: 1098-1106
2. Beavon IR (2000) The E-cadherin-catenin complex in metastasis: Structure, function and regulation. Eur J Cancer 36: 1607-1620
3. Berx G, Van Roy F (2001) The E-cadherin/catenin complex: An important gatekeeper in breast cancer igenesis and malignant progression. Breast Cancer Res 3: 289-293
4. Birchmeier W, Behrens J (1994) Cadherin expression in carcinomas: Role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198: 11-26
5. Bukholm IK, Nesland JM, Karesen R (1998) E-cadherin and alpha-, beta-, and gamma-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 185: 262-266
6. Cavallaro U, Schaffhauser B, Cristofori G (2002) Cadherins and the progression: Is it in a switch? Cancer Lett 176: 123-128
7. Christofori G (2003) Changing neighbours, changing behaviour: Cell adhesion molecule-mediated signalling during progression. EMBO J 22: 2318-2323
8. Friedl P, Hegerfeldt Y, Tusch M (2004) Collective cell migration in morphogenesis and cancer. Int J Dev Biol 48: 441-449
9. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W (1991) E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113: 173-185
10. Gillett CE, Miles DW, Ryder K, Skilton D, Liebman RD, Springgall RJ, Barnes DM, Hanby AM (2001) Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol 193: 433-441
11. Gould Rothberg BE, Bracken MB (2006) E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: A systematic review and meta-analysis. Breast Cancer Res Treat 100: 139-148
12. Greenacre MJ (1994) Theory and Applications of Correspondence Analysis. Academic Press: New York
13. Harigopal M, Berger AJ, Camp RL, Rimm Dl, Kluger HM (2005) Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clin Cancer Res 11: 4083-4089
14. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA (2000) Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol 148: 779-790
15. Heimann R, Lan F, McBride R, Hellman S (2000) Separating favourable from unfavorable prognostic markers in breast cancer: The role of E-cadherin. Cancer Res 60: 298-304
16. Hirohashi S (1998) Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 153: 333-339
17. Howard EM, Lau SK, Lyles RH, Birdsong GC, Tadros TS, Umbreit JN, Kochar R (2004) Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breastcancer population. Int J Clin Oncol 9: 154-160
18. Howard EM, Lau SK, Lyles RH, Birdsong GC, Umbreit JN, Kochar R (2005) Expression of E-cadherin in high-risk breast cancer. J Cancer Res Clin Oncol 131: 14-18
19. Jeschke U (2007) Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence. Anticancer Res 27: 1969-1974
20. Kantak SS, Kramer RH (1998) E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J Biol Chem 273: 16953-16961
21. Kaufman L, Rousseeuw PJ (1990) Finding Groups in Data: An Introduction to Cluster Analysis. Wiley: New York
22. Kleer CG, van Golen KL, Braun T, Merajver SD (2001) Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol 14: 458-464
23. Kowalski PJ, Rubin MA, Kleer CG (2003) E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 5: R217
24. Lim SC, Lee MS (2002) Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer. Oncol Rep 9: 915-928
25. Lipponen P, Saarelainen E, Ji H, Aaltomaa S, Syrjanen K (1994) Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer. J Pathol 174: 101-109
26. Marubini E, Valsecchi MG (1995) Analysing Survival Data from Clinical Trials and Observational Studies. John Wiley & Sons: Chichester
27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommitee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) Reporting recommendations for tumour marker prognostic studies (REMARK). J Natl Cancer Inst 97: 1180-1184 (Pubitemid 41258223)
28. Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, Kawaguchi Y, Fujimoto K, Hosotani R, Imamura M (2004) N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 10: 4125-4133
29. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ (1999) N-Cadherin Promotes motility in human breast cancer cells regardless of their E-Cadherin expression. J Cell Biol 147: 631-643
30. Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC (2005) P-Cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 11: 5869-5877
31. Parker C, Rampaul RS, Pinder SE, Bell JA, Wencyk PM, Blamey RW, Nicholson RI, Robertson JF (2001) E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer 85: 1958-1963
32. Pedersen KB, Nesland JM, Fodstad O, Maelandsmo GM (2002) Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies. Br J Cancer 87: 1281-1286
33. Qureshi HS, Linden MD, Divine G (2006) E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters. Am J Clin Pathol 125: 377-385
34. Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO (2005) E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 46: 685-693
35. Schoenfeld D (1982) Partial residuals for the proportional hazard regression model. Biometrica 69: 239-341
36. St Croix B, Kerbel RS (1997) Cell adhesion and drug resistance in cancer. Curr Opin Oncol 9: 549-556
37. Stefansson IM, Salvesen HB, Akslen LA (2004) Prognostic impact of alteration in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 22: 1242-1252
38. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ETG, Jansen CFJ, Bussemakers MJG, Schalken JA (2000) Cadherin switching in human prostate cancer progression. Cancer Res 60: 3650-3654 (Pubitemid 30482189)
39. Walter SD, Feinstein AR, Wells CK (1987) Coding ordinal independent variables in multiple regression analyses. Am J Epidemiol 125: 319-323